Novo Nordisk Licenses Factor XIII Portfolio From ZymoGenetics
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is discussing the pivotal trial program for Factor XIII with FDA following the agreement. Novo Nordisk expects to initiate clinical studies in fibrinolysis-induced bleeding next year.
You may also be interested in...
Rare Protein Disorder Workshop To Address Treatment Development Challenges
FDA-sponsored June 13-14 workshop will seek ways of facilitating development of treatments for small patient populations. The workshop will include presentations by Novo Nordisk, GTC Therapeutics, Baxter and ZLB Behring.
Rare Protein Disorder Workshop To Address Treatment Development Challenges
FDA-sponsored June 13-14 workshop will seek ways of facilitating development of treatments for small patient populations. The workshop will include presentations by Novo Nordisk, GTC Therapeutics, Baxter and ZLB Behring.
Serono Broadens Research Pipeline With ZymoGenetics Alliance
Serono will pay over $81 mil. upfront for access to ZymoGenetics’ therapeutic protein research. The deal includes a license to products based on three proteins that could expand Serono’s presence in inflammation and autoimmune disease.